GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Minority Interest

TECX (Tectonic Therapeutic) Minority Interest : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Tectonic Therapeutic's minority interest for the quarter that ended in Mar. 2025 was $0.00 Mil.


Tectonic Therapeutic Minority Interest Historical Data

The historical data trend for Tectonic Therapeutic's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Minority Interest Chart

Tectonic Therapeutic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Minority Interest
- - - -

Tectonic Therapeutic Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tectonic Therapeutic Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Tectonic Therapeutic Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.